RS102221 HCl
| CAS No. | 185376-97-0 | Cat. No. | BCP03496 |
| Name | RS102221 HCl | ||
| Synonyms | RS 102221 HCl;RS-102221 HCl; | ||
| Formula | C27H32ClF3N4O7S | M. Wt | 649.08 |
| Description | RS-102221 is a drug developed by Hoffmann–La Roche, which was one of the first compounds discovered that acts as a potent and selective antagonist at the serotonin 5-HT2C receptor, with around 100x selectivity over the closely related 5-HT2A and 5-HT2B receptors. It has anxiolytic effects in animal studies, increases the effectiveness of SSRI antidepressants, and shows a complex interaction with cocaine, increasing some effects but decreasing others, reflecting a role for the 5-HT2C receptor in regulation of the dopamine signalling system in the brain. | ||
| Pathways | Neuro Signaling Pathway GPCR/G Protein | ||
| Targets | 5 HT Receptor/Serotonin Receptor | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.